These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31681591)

  • 1. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
    Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
    Front Oncol; 2019; 9():1055. PubMed ID: 31681591
    [No Abstract]   [Full Text] [Related]  

  • 2. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
    Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
    Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
    Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
    J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
    Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
    Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
    Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
    Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression.
    Stergiou IE; Palamaris K; Levidou G; Tzimou M; Papadakos SP; Mandrakis G; Masaoutis C; Rontogianni D; Theocharis S
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
    Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
    Koh HM; Jang BG; Lee HJ; Hyun CL
    Thorac Cancer; 2020 Nov; 11(11):3086-3098. PubMed ID: 32926538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
    Higuchi R; Goto T; Hirotsu Y; Nakagomi T; Yokoyama Y; Otake S; Amemiya K; Oyama T; Omata M
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31683962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
    Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
    Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic tumors and immune checkpoint inhibitors.
    Yokoyama S; Miyoshi H
    J Thorac Dis; 2018 May; 10(Suppl 13):S1509-S1515. PubMed ID: 29951302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
    Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
    Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients.
    Liang N; Liu L; Huang C; Liu H; Guo C; Li J; Wang W; Li N; Lin R; Wang T; Ding L; Mao L; Li S
    Front Oncol; 2021; 11():647512. PubMed ID: 34568003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 19. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
    Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
    Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
    Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
    Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.